Otoacoustic emissions at compensated middle ear pressure: preliminary results

2003 ◽  
Vol 1254 ◽  
pp. 159-163
Author(s):  
J.R Hof ◽  
P van Dijk ◽  
M.N Chenault ◽  
L.J.C Anteunis
1998 ◽  
Vol 118 (5) ◽  
pp. 584-588 ◽  
Author(s):  
Gregory C. Allen ◽  
Christopher Tiu ◽  
Kazunari Koike ◽  
A. Kim Ritchey ◽  
Marcia Kurs-Lasky ◽  
...  

Little is known about cisplatin ototoxicity in pediatric patients. Measurement of otoacoustic emissions is a rapid, reproducible, objective method of evaluating hearing. We examined whether transient-evoked otoacoustic emissions in pediatric patients exposed to cisplatin in the past correlated with audiographic findings. Twelve patients were entered into the study (mean age at treatment 7.8 years, mean cumulative dose 442.5 mg/mm2, mean 7.1 doses). Hearing at 3000 Hz was preserved in 82.6% of patients. In the higher frequencies significant sensorineural hearing loss was noted: 43.5% at 4 kHz; 81.0% at 6 kHz; and 90.5% at 8 kHz. Transient-evoked otoacoustic emissions were measurable in 11 of 12 patients. Middle ear disease accounted for abnormal otoacoustic emission seen in three patients (1 with effusion, 2 with significant negative middle ear pressure). When the middle ear was normal, a statistically significant correlation was seen between the transient-evoked otoacoustic emissions reproducibility and pure-tone threshold (correlation coefficient = −0.69, p = 0.008). Increased hearing loss was also associated with young age at first dose of cisplatin ( p = 0.044), high number of chemotherapy cycles ( p = 0.042), and high cumulative dose ( p = 0.042). (Otolaryngol Head Neck Surg 1998;118:584–8.)


1997 ◽  
Vol 18 (3) ◽  
pp. 218-226 ◽  
Author(s):  
Lynne Marshall ◽  
Laurie M. Heller ◽  
Linda J. Westhusin

1993 ◽  
Vol 14 (6) ◽  
pp. 401-407 ◽  
Author(s):  
Mary Beth Trine ◽  
Judith E. Hirsch ◽  
Robert H. Margolis

2005 ◽  
Vol 44 (6) ◽  
pp. 317-320 ◽  
Author(s):  
J. R. Hof ◽  
L. J. C. Anteunis ◽  
M. N. Chenault ◽  
P. van Dijk

2021 ◽  
pp. 1-7
Author(s):  
Giovanna Zimatore ◽  
Piotr Henryk Skarzynski ◽  
Federica Di Berardino ◽  
Eliana Filipponi ◽  
Stavros Hatzopoulos

Introduction: Recently, Interacoustics presented a new otoacoustic emission protocol where the probe pressurizes the ear cavity, thus eliminates the risk of non-assessment (REFER outcome) due to a negative middle ear pressure. This study evaluated the characteristics and the performance of this new protocol on a newborn well-baby population. Methods: One hundred sixty-three newborns (age 2.7 ± 1.1 days) for a total of 294 ears were assessed randomly. Transiently evoked otoacoustic responses were acquired by the Titan device (Interacoustics), using the default and a pressurized TEOAE protocol. The data were analyzed in terms of signal to noise ratios (S/Ns) at 5 frequencies, namely, 0.87, 1.94, 2.96, 3.97, and 4.97 kHz. To assess any possible gestational age (GE) effects on the TEOAE variables, the responses were subdivided in 4 different age subgroups. Results: There were no significant differences between the left and right ear TEOAE responses, for age (in days), GE (in weeks), weight (in grams), and S/N at all 5 frequencies. Considering the pooled 294 ears, paired t tests between the default and the pressurized TEOAE data showed significant differences across all 5 frequencies (p < 0.01). The pressurized protocol generated TEOAE responses presenting larger S/Ns, and a positive additive effect of approximately 2.31 dB was observed at all tested frequencies. There were no significant GE effects on the pressurized TEOAE responses. In terms of performance, both protocols performed equally (same number of PASSes). Conclusion: The pressurized TEOAE protocol generates responses with higher S/Ns which might be useful in borderline cases where the middle ear status might cause a REFER screening outcome.


1996 ◽  
Vol 39 (6) ◽  
pp. 701-706
Author(s):  
Hiromi Ueda ◽  
Hayato Tsuge ◽  
Noriyuki Yanagita

Sign in / Sign up

Export Citation Format

Share Document